The EURO-FORTA (Fit fOR The Aged) List Version 2: Consensus Validation of a Clinical Tool for Improved Pharmacotherapy in Older Adults

Drugs & Aging

Farhad Pazan[1], Christel Weiss[2], Martin Wehling[1] *FORTA

Affiliations:

1 Clinical Pharmacology Mannheim, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany

2 Department of Medical Statistics, Biomathematics and Information Processing, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany

Corresponding author:
Dr. Farhad Pazan
e-mail: farhad.pazan@medma.uni-heidelberg.de
Phone: +49 621 383 9629

The EURO - F O R T A list *Version 2*

"Fit fOR The Aged"

Expert Consensus Validation

Farhad Pazan[1], Christel Weiß[2], Martin Wehling[1]
[1]Institute of Clinical Pharmacology, Center for Geriatric Pharmacology, Medical Faculty of the University of Heidelberg in Mannheim, Germany
[2] Department of Medical Statistics, Biomathematics and Information Processing, Medical Faculty of the University of Heidelberg in Mannheim, Germany

Disclaimer

While building on an international foundation of medical evidence and experience for the medications listed, including already existing "negative lists" and classification systems, this FORTA List primarily reflects prescribing tendencies in seven European countries/regions. The FORTA labels themselves, being evidence-based, may possibly be subject to change during the course of further consensus evaluation procedures, depending on the state of evidence and clinical experience for a given substance[5]. Meanwhile, the FORTA principle has been validated in a randomized clinical trial (VALFORTA) showing a large improvement of medication quality and amelioration of clinical parameters[6].

With the goal of creating a user-friendly clinical tool, a summary of relevant comments is given directly in the EURO-FORTA List, drawing on the Delphi experts' extensive clinical experience. This is however by no means comprehensive and does not necessarily refer to specific evidence or sources. Therefore, the authors' selection of suggestions, comments and warnings may be subjective[5]. 'No comment' reflects the absence of noteworthy or relevant words of information or caution within the context of the expert evaluation. All information herein is believed to be true and accurate. Neither the authors nor the University of Heidelberg or affiliated institutions, as the publishers of this list, can accept legal responsibility for any errors or omissions made in the contents of this list[5].

We welcome all comments and criticism which may contribute to the quality, safety and usability of the EURO-FORTA List in daily clinical practice.

The FORTA Concept: expert panel for the FORTA classification system

FORTA Expert Review Panel

The following 48 colleagues, representing seven European countries/regions, provided their expertise for purposes of evaluating the proposed FORTA List. They received no honoraria in connection with this project. All panel members contributed actively to the development of the content of the EURO-FORTA List.

Expert Panel Members and their affiliations

Katarzyna Wieczorowska-Tobis, MD, PhD: Laboratory for Geriatric Medicine, Department of Palliative Medicine, Karol Marcinkowski University of Medical Sciences, Poznan

Tomasz Kostka, MD: Department of Geriatrics, Healthy Ageing Research Centre, Medical University of Lodz, Lodz

Alicja Klich-Rączka, MD: Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, Krakow

Barbara Bień, MD: Department of Geriatrics, Medical University of Bialystok, Bialystok

Marlena Broncel, PhD: Department of Internal Diseases and Clinical Pharmacology, Medical University of Łódź, Lodz

Pawel Mierzejewski, MD: Department of Pharmacology, Institute of Psychiatry and Neurology, Warsaw

Agnieszka Neumann-Podczaska Department of Palliative Medicine, Poznan University of Medical Sciences, 61-245 Poznan

Graziano Onder, MD: Department of Geriatrics, Centro Medicina dell'Invecchiamento, Università Cattolica del Sacro Cuore, Rome, Italy

Raffaele Antonelli Incalzi, MD: Unit of Geriatrics, Campus Bio-Medico University, Rome

Antonio Cherubini, MD: Geriatrics and Geriatric Emergency Care, IRCCS-INRCA, Ancona

Carmelinda Ruggiero, MD: Institute of Gerontology and Geriatrics, Department of Medicine, University of Perugia, Perugia

Alessandro Mugelli, MD: Department of Neurosciences, Psychology, Drug Research and Children's Health, University of Florence, Florence, Italy

Kristina Johnell, PhD: Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden

Tommy Eriksson, PhD: Malmö University, Faculty of Health and Society, Malmö, Sweden

Ulla Aalto Department of Geriatrics, Helsinki University Hospital, University of Helsinki, Finland

Adalsteinn Gudmundsson Landspitali University Hospital Reykjavik, Landspitali, Iceland

Leocadio Rodríguez Mañas, MD: Servicio de Geriatría, Hospital Universitario de Getafe, 28905 Getafe

Alfonso Jose Cruz Jentoft, MD: Servicio de Geriatría, Hospital Universitario Ramón y Cajal, Madrid

José Antonio Serra Rexach, MD: Servicio de Geriatría, Hospital General Universitario Gregorio Marañón, Madrid

Antònia Agustí, MD: Servei de Farmacologia Clínica, Fundació Institut Català de Farmacologia, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona

Rob van Marum Department of General Practice and Old Age Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Eveline P.van Poelgeest Amsterdam UMC location University of Amsterdam, Internal Medicine, Section of Geriatric Medicine, Meibergdreef 9, Amsterdam, The Netherlands

Patricia M. L. A. van den Bemt, PhD: Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands

Tischa J. M. van der Cammen, MD: Erasmus University Medical Center, Section of Geriatric Medicine, Department of Internal Medicine, Rotterdam, The Netherlands

Peter Crome, MD: Department of Primary Care and Population Health, University College London; and Emeritus Professor of Geriatric Medicine, Keele University, Keele

Denis O'Mahony, MD: Department of Medicine, University College Cork & Consultant Geriatrician, Cork University Hospital, Wilton, Cork, Ireland

Stephen Byrne, PhD: School of Pharmacy, Cavanagh Pharmacy Building, University College Cork, Ireland

Roy L. Soiza, MD: Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN

Jürgen M. Bauer, MD: Geriatrie der Medizinischen Fakultät - Universität Heidelberg, AGAPLESION Bethanien Krankenhaus Heidelberg gemeinnützige GmbH, Rohrbacher Straße 149, 69126 Heidelberg, Germany

Heiner K. Berthold, MD: Klinik für Innere Medizin und Geriatrie, Evangelisches Klinikum Bethel, Universitätsklinikum OWL der Universität Bielefeld, Campus Bielefeld-Bethel, Schildescher Straße 99, 33611 Bielefeld, Germany

Michael Denkinger, MD: AGAPLESION Bethesda Klinik Ulm, Akademisches Krankenhaus der Universität Ulm, Zollernring 26, 89073 Ulm, Germany

Christine von Arnim, MD: Universitätsmedizin Göttingen, Georg-August-Universität, Robert-Koch-Str., 37075 Göttingen, Germany

Peter Dovjak, MD: LKH Gmunden, Zentrum für Akutgeriatrie/Remobilisation, Miller von Aichholzstraße 49, 4810 Gmunden, Austria

Helmut Frohnhofen, MD: Klinik für Nephrologie, Altersmedizin und Innere Medizin, Alfried Krupp Krankenhaus Rüttenscheid, Alfried-Krupp-Straße 21, 45131 Essen, Germany

Markus Gosch, MD: Medizinische Klinik 2, Schwerpunkt Geriatrie, Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Klinikum Nürnberg, Prof.-Ernst-Nathan-Str. 1, 90419 Nürnberg, Germany

Hans Gutzmann, MD: Krankenhaus Hedwigshöhe, Klinik für Psychiatrie und Psychotherapie, Höhensteig 1, 12526 Berlin, Germany

Isabella Heuser-Collier, MD: Charité-Universitätsmedizin Berlin, Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Hindenburgdamm 30, 12203 Berlin, Germany

Friedemann Honecker, MD: FMH Innere Medizin, spez. Hämatologie / Onkologie**,** Tumor- und Brustzentrum ZeTuP, Silberturm, Rorschacherstrasse 150, 9006 St. Gallen, Switzerland

Michael Hüll, MD: Klinik für Alterspsychiatrie- und psychotherapie, Zentrum für Psychiatrie Emmendingen, Neubronnstr. 25, 79312 Emmendingen, Germany

Bernhard Iglseder, MD: Uniklinikum Salzburg, Christian-Doppler-Klinik, Universitätsklinik für Geriatrie der PMU, Ignaz-Harrer-Straße 79, 5020 Salzburg, Austria

Ulrich Jaehde, PhD: Rheinische Friedrich-Wilhelms-Universität Bonn, Pharmazeutisches Institut, Klinische Pharmazie, An der Immenburg 4, 53121 Bonn, Germany

Reto W. Kressig, MD: Klinische Professur für Geriatrie, Universität Basel, Memory Clinic,Universitäre Altersmedizin, Burgfelderstrasse 101, 4055 Basel, Switzerland

Anja Kwetkat, MD: Universitätsklinikum Jena, Klinik für Geriatrie, Bachstraße 18, 07743 Jena, Germany

Christoph Schindler, MD: frühe klinische Studien und Arzneiforschung, CRC Core Facility, OE 8660, Medizinische Hochschule Hannover (MHH), Feodor-Lynen-Strasse 15, 30625 Hannover, Germany

Ralf-Joachim Schulz, MD: Klinik für Geriatrie am St.-Marien-Hospital, Kunibertkloster 11-13 50668 Köln, Germany

Andrej Zeyfang, MD: Klinik für Innere Medizin, Altersmedizin und Palliativmedizin, medius KLINIK OSTFILDERN-RUIT
Akademisches Lehrkrankenhaus der Universität Tübingen, Hedelfinger Str. 166, 73760 Ostfildern, Germany

Sophie Pautex, MD: HÔPITAUX UNIVERSITAIRES GENÈVE, Rue Gabrielle-Perret-Gentil 4, 1205 Genève, Switzerland

Ulrich Wedding, MD: Klinik für Innere Medizin II, Universitätsklinikum Jena, Erlanger Allee 101, 07740 Jena, Germany

F O R T A – Physician's guide[1,2,5,7]

1. **FORTA is evidence-based + real-life-oriented (factors such as compliance issues, age-dependent tolerance and frequency of relative contraindications are considered).**

2. **Classifications are indication (or diagnosis)-dependent: a medication can receive different FORTA classifications based on differing indications.**

3. **Contraindications always take precedence over the FORTA-classification (for example, even Class A medications may not be given if allergies are present).**

4. **FORTA is designed to be a quick and user-friendly clinical tool to aid in the pharmacotherapy of older patients*. The system is not intended to take the place of individual therapeutic considerations or decisions. As with any simplified model, it does allow for exceptions.**

F O R T A – Classification System A-D[1,2,3,4,7]

Class A	Class B	Class C	Class D
= Indispensable drug, clear-cut benefit in terms of efficacy/safety ratio proven in elderly patients for a given indication	= Drugs with proven or obvious efficacy in the elderly, but limited extent of effect and/or safety concerns	= Drugs with questionable efficacy/safety profiles in the elderly which should be avoided or omitted in the presence of too many drugs, absence of benefits or emerging side effects; explore alternatives	= Avoid if at all possible in the elderly, omit first and use alternative substances

*** FORTA aims at older patients, has been validated primarily for patients 65 years of age or older with significant comorbidities (3 or more diagnoses and drugs) and should be used in all patients 80 years of age or older will. These target groups are mostly defined as geriatric patients.**

The EURO-F O R T A List[3,4,5]
Delphi Expert Consensus Validation

F O R T A			
A	B	C	D

Classification of the most frequently used long-term medications†
for the pharmacotherapy of older patients
by indication/diagnosis, ranked according to FORTA classification
Newly proposed drugs are mentioned under the respective diagnosis and marked by *; they are listed in greater detail in the second part.

(† long-term defined as > 4 weeks. Please note that the distinction between acute/chronic may not always be clear-cut; exceptions are noted)

ARTERIAL HYPERTENSION	**Suggested FORTA class (2018)[8]; if different marked with ***	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland[9] (N=20)** FORTA class / Consensus coefficient	**Mean consensus coefficient**	**EURO-FORTA Class** (Original FORTA class in parentheses if different from consensus results)
Substance/Group										
Renin-Angiotensin system inhibitors **ACE inhibitors**	**A**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**1.000**	**A**
Angiotensin receptor antagonists	**A**	**A** **1.000**	**A** **1.000**	**A** **0.875**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**0.982**	**A**
Long-acting calcium antagonists, dihydropyridine type, for example amlodipine	**A**	**A** **1.000**	**A** **0.900**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**0.986**	**A**
Betablockers except atenolol	**C***	**C** **0.875**	**C** **0.900**	**B** **0.667**	**C** **0.875**	**C** **0.857**	**C** **1.000**	**C** **0.895**	**0.867**	**C**
Atenolol	**D***	**D** **0.750**	**D** **0.900**	**D** **0.667**	**D** **0.875**	**D** **1.000**	**C** **0.750**	**D** **1.000**	**0.849**	**D**
Diuretics except indapamid	**B**	**B** **1.000**	**B** **0.800**	**B** **0.875**	**B** **0.833**	**B** **1.000**	**B** **1.000**	**B** **0.972**	**0.926**	**B**
Indapamid	**A***	**B** **0.750**	**A** **0.900**	**A** **0.833**	**A** **1.000**	**A** **1.000**	**B** **0.625**	**A** **0.833**	**0.849**	**A**

Alpha blockers	**C**	**C** **0.875**	**C** **0.900**	**C** **1.000**	**C** **1.000**	**C** **0.833**	**C** **1.000**	**C** **0.974**	**0.940**	**C**
Spironolactone	**C**	**C** **0.875**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **0.972**	**0.978**	**C**
Moxonidine	**C**	**C** **0.750**	**C** **0.875**	**C** **0.833**	**C** **1.000**	**C** **0.917**	**C** **1.000**	**C** **1.000**	**0.911**	**C**
Aliskiren	**C**	**C** **1.000**	**C** **1.000**	**C** **-**	**C** **1.000**	**C** **0.900**	**C** **1.000**	**C** **0.971**	**0.978**	**C**
Urapidil	**C**	**C** **0.833**	**C** **1.000**	**-**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**0.972**	**C**
Clonidine	**D**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **0.972**	**0.996**	**D**
Minoxidil	**D**	**D** **1.000**	**D** **1.000**	**D** **0.500**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**0.929**	**D**
Calcium antagonists, verapamil type	**D**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**C** **0.857**	**D** **1.000**	**D** **1.000**	**0.980**	**D**
CARDIAC INSUFFICIENCY	**Suggested FORTA class (2018); if different marked with ***	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland [9] (N=20)** FORTA class / Consensus coefficient	**Mean consensus coefficient**	**EURO-FORTA Class** (Original FORTA class in parentheses if different from consensus results)
Substance/Group										

Renin-angiotensin system inhibitors **ACE inhibitors**	**A**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**1.000**	**A**
Angiotensin receptor antagonists	**A**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**1.000**	**A**
Betablockers (metoprolol, carvedilol, bisoprolol)	**A**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **0.974**	**0.996**	**A**
Diuretics	**B**	**A** **0.625**	**A** **1.000**	**A** **0.875**	**A** **1.000**	**A** **1.000**	**B** **1.000**	**B** **0.921**	**0.917**	**(B)** **A**
Gliflozins (SGLT2 inhibitors) only those substances which have been approved for this indication (dapgliflozine)	**B**	**B** **1.000**	**B** **0.900**	**B** **1.000**	**B** **0.875**	**B** **0.917**	**B** **0.875**	**B** **0.971**	**0.934**	**B**
Spironolactone	**B**	**B** **1.000**	**B** **0.800**	**C** **1.000**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**C** **0.947**	**0.964**	**B**
Digitalis preparations	**C**	**C** **1.000**	**C** **0.900**	**C** **1.000**	**C** **0.875**	**C** **1.000**	**C** **1.000**	**C** **0.947**	**0.960**	**C**
Ivabradine	**C**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **0.972**	**0.996**	**C**
Iron substitution in patients with iron deficiency	**A**	**A** **1.000**	**A** **1.000**	**A** **0.875**	**A** **1.000**	**A** **0.929**	**A** **1.000**	**A** **0.895**	**0.957**	**A**

ACUTE CORONARY SYNDROME	**Suggested FORTA class (2018); if different marked with ***	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland[9] (N=20)** FORTA class / Consensus coefficient	**Mean consensus coefficient**	**EURO-FORTA Class** (original FORTA class in parentheses if different from consensus results)
Substance/Group										
Renin-Angiotensin-System- Blocker: ACE inhibitors	**A**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**1.000**	**A**
Acetylsalicylic acid	**A**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**1.000**	**A**
Unfractionated heparin and low molecular weight heparin	**A**	**A 0.750**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**0.964**	**A**
Frequency-lowering betablockers , e.g. metoprolol or bisoprolol	**A**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**1.000**	**A**
Atorvastatin	**A**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**1.000**	**A**
Nitroglycerin spray, single use, acute as on-demand medication	**A**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 0.929**	**A 1.000**	**A 0.947**	**0.982**	**A**
Clopidogrel, prasugrel	**B**	**B 0.875**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**A 1.000**	**A 1.000**	**0.982**	**B**

	A for stent	**A for stent 1.000**	**A for stent 1.000**	**A for stent 1.000**	**A for stent 1.000**	**A for stent 0.857**	**A for stent 1.000**		**0.976**	**A for stent**
Thrombolytics, especially rTPA (recombinant tissue-type plasminogen activator)	**B**	**C 1.000**	**B 0.833**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**0.976**	**B**
Nitrates, long-term	**C**	**B 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 0.917**	**C 1.000**	**C 0.947**	**0.981**	**C**
Gp IIb/IIIa antagonists (glycoprotein 2b/3a inhibitors)	**C**	**B 0.875**	**C 1.000**	**C 1.000**	**C 1.000**	**C 0.917**	**C 0.875**	**C 1.000**	**0.952**	**C**
Ivabradine	**C**	**B 0.750**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**0.964**	**C**
CHRONIC THERAPY FOLLOWING MYOCARDIAL INFARCTION	**Suggested FORTA class (2018); if different marked with ***	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland [9](N=20)** FORTA class / Consensus coefficient	**Mean consensus coefficient**	**EURO-FORTA Class** (original FORTA class in parentheses if different from consensus results)
Substance/group										
Renin angiotensin system blockers ACE Inhibitors	**A**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**1.000**	**A**
Acetylsalicylic acid (100 mg/d)	**A**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**1.000**	**A**

Frequency-lowering beta blockers up to 3 years **Frequency-lowering beta blockers longer than 3 years**	**A** **C**	**A** **1.000** **C** **0.833**	**A** **1.000** **C** **1.000**	**A** **1.000** **C** **1.000**	**A** **1.000** **C** **1.000**	**A** **1.000** **B** **0.786**	**A** **1.000** **B** **1.000**	**A** **1.000** **C** **0.917**	**1.000** **0.934**	**A** **C**
Nitroglycerin spray, single use as on-demand medication	**A**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **0.929**	**A** **1.000**	**A** **0.921**	**0.979**	**A**
Influenza vaccination (inactivated subunit vaccines)/pneumococcal immunizations	**See Vaccinations**	-	-	-	-	-	-	-	-	-
Statins	**A** **B** for very old (>85 years) patients	**A** **1.000** **B** **0.875**	**A** **1.000** **B** **0.800**	**A** **1.000** **B** **0.875**	**A** **1.000** **B** **1.000**	**A** **0.917** **B** **0.875**	**A** **1.000** **B** **1.000**	**A** **1.000** **B** **0.895**	**0.988** **0.903**	**A** **B** **for very old (>85 years) patients**
Clopidogrel (12 months after acute coronary syndrome)	**A** with aspirin intolerance	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**1.000**	**A** **with aspirin intolerance**
Nitrates, long-term	**C**	**C** **1.000**	**C** **0.875**	**C** **1.000**	**C** **0.875**	**C** **0.857**	**C** **1.000**	**C** **0.947**	**0.936**	**C**
Fibrates	**C**	**C** **0.875**	**C** **0.875**	**C** **1.000**	**C** **1.000**	**C** **0.929**	**C** **1.000**	**C** **0.921**	**0.943**	**C**
Ezetimibe	**C**	**C** **0.875**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **0.929**	**C** **1.000**	**B** **1.000**	**0.972**	**C**
Amiodarone **All other class-I/III antiarrhythmic agents**	**C** **D**	**D** **1.000** **D** **1.000**	**C** **0.875** **D** **1.000**	**C** **1.000** **D** **1.000**	**C** **1.000** **D** **1.000**	**C** **1.000** **D** **1.000**	**C** **1.000** **D** **0.875**	**C** **0.972** **D** **1.000**	**0.978** **0.982**	**C** **D**

Dihydropyridine antagonists (if no hypertension)	**D**	**D 0.875**	**D 1.000**	**D 0.875**	**D 1.000**	**D 1.000**	**D 0.875**	**D 1.000**	**0.946**	**D**
Niacin	**D**	**D 1.000**	**D 1.000**	**D 0.500**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**0.929**	**D**

STROKE	**Suggested FORTA class (2018); if different marked with ***	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland[9] (N=20)** FORTA class / Consensus coefficient	**Mean consensus coefficient**	**EURO-FORTA Class** (original FORTA class in parentheses if different from consensus results)
Substance/Group										
Acetylsalicylic acid	**A**	**B 0.750**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**0.964**	A
Atorvastatin	**A**	**A 0.875**	**A 1.000**	**A 0.875**	**A 0.875**	**A 1.000**	**B 1.000**	**A 1.000**	**0.938**	**A**
rTPA (recombinant tissue-type plasminogen activator); only for emergency use	**A**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**1.000**	**A**
Simvastatin	**A**	**A 0.875**	**A 1.000**	**A 0.875**	**A 0.875**	**B 0.714**	**A 0.875**	**A 1.000**	**0.869**	**A**
Anticoagulants including new oral anticoagulants	**A**	**B 0.875**	**A 1.000**	**A 0.875**	**A 1.000**	**A 1.000**	**A 1.000**	**-**	**0.958**	**A**

Clopidogrel	**A**	**A** **0.625**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**0.946**	**A**
Dipyridamole plus acetylsalicylic acid	**B**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**B** **0.875**	**B** **1.000**	**C** **1.000**	**C** **0.947**	**0.975**	**B**

ATRIAL FIBRILLATION	**Suggested FORTA class (2018); if different marked with ***	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland[9] (N=20)** FORTA class / Consensus coefficient	**Mean consensus coefficient**	**EURO-FORTA Class** (original FORTA class in parentheses if different from consensus results)
Substance/group										
Frequency-lowering betablockers	**A**	**A** **0.875**	**A** **0.900**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**0.968**	**A**
New Oral Anticoagulants (NOACs)	**B**	**A** **0.750**	**A** **0.700**	**B** **0.833**	**B** **0.750**	**A** **0.714**	**B** **1.000**	**B** **0.895** **(Apixaban FORTA A)**	**0.806**	**B**
Except dabigatran	**C**	**C** **0.667**	**C** **0.900**	**B** **0.500**	**C** **1.000**	**C** **0.900**	**C** **0.875**	**B** **0.895**	**0.732**	**C**
Oral anticoagulation by vitamin-K-	**B**	**B** **0.875**	**B** **0.900**	**B** **0.750**	**B** **0.875**	**B** **0.929**	**B** **1.000**	**B** **0.972**	**0.900**	**B**

antagonists (e.g. phenprocoumon, warfarin) Alternative: low molecular weight heparin								(Phenprocoumon C)		
	C	C 0.875	C 1.000	C 1.000	C 0.875	C 1.000	C 1.000	C 1.000	0.964	C
Digoxin	B	B 0.750	B 0.800	C 1.000	B 1.000	B 0.714	B 0.875	C 0.944	0.869	B
Digitoxin	C	C 0.833	C 0.875	C 1.000	C 1.000	C 0.700	C 0.875	C 0.944	0.890	C
Diltiazem, verapamil	C	C 1.000	C 1.000	C 0.667	C 1.000	C 0.929	C 1.000	D 1.000	0.942	C
Class III antiarrhythmic agent amiodarone All other class I or III antiarrhythmic agents	C	C 1.000	C 0.800	C 1.000	C 1.000	C 0.857	C 1.000	C 0.947	0.943	C
	D	D 0.875	D 1.000	D 1.000	D 1.000	D 1.000	D 1.000	D 1.000	0.983	D
Acetylsalicylic acid (100 mg/d)	D	D 1.000	D 0.800	C 1.000	D 0.667	C 0.917	D 1.000	D 1.000	0.912	D
Class III antiarrhythmic agent dronedarone	D	D 0.833	D 1.000	D 1.000	D 1.000	D 1.000	D 1.000	D 1.000	0.976	D

0.957										
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)	**Suggested FORTA class (2018); if different marked with ***	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland[9] (N=20)** FORTA class / Consensus coefficient	**Mean consensus coefficient**	**EURO-FORTA Class** (original FORTA class in parentheses if different from consensus results)
Substance/group										
Inhalative long-acting parasympatholytic agents	**A**	**A 1.000**	**A 1.000**	**A 0.875**	**A 1.000**	**A 1.000**	**A 0.875**	**A 1.000**	**0.964**	**A**
Systemic glucocorticoids, acute, short-term use in cases of exacerbation	**A**	**A 1.000**	**A 1.000**	**A 0.875**	**A 1.000**	**A 0.833**	**A 1.000**	**A 0.972**	**0.954**	**A**
Antibiotics (acute) in cases of exacerbation, after calculated selection and, if necessary, according to antibiogram	**A**	**A 1.000**	**A 1.000**	**A 0.833**	**A 1.000**	**A 0.917**	**A 1.000**	**A 1.000**	**0.964**	**A**
Long-term administration of oxygen	**A**	**A 1.000**	**A 1.000**	**A 0.875**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**0.982**	**A**
Annual influenza immunizations	**See vaccinations**	-	-	-	-	-	-	-	-	-

Pneumococcal immunizations for persons ≥ 65 years	**See Vaccinations**	-	-	-	-	-	-	-	-	-
Inhalative beta 2 mimetic agents	**B**	**B** **0.750**	**B** **1.000**	**B** **0.833**	**B** **1.000**	**B** **0.917**	**B** **1.000**	**B** **0.912**	**0.916**	**B**
Inhalative glucocorticoids	**C**	**C** **0.875**	**C** **0.800**	**B** **0.667**	**C** **0.875**	**B** **0.917**	**C** **1.000**	**C** **0.917**	**0.864**	**C**
Theophylline	**D***	**D** **1.000**	**D** **0.875**	**D** **1.000**	**D** **1.000**	**D** **0.833**	**D** **1.000**	**D** **1.000**	**0.958**	**D**
Mucolytic agents, e,g, acetyl cysteine, bromhexine	**C**	**D** **1.000**	**C** **0.900**	**C** **1.000**	**C** **1.000**	**C** **0.917**	**C** **0.875**	**C** **0.972**	**0.952**	**C**
Roflumilast	**C**	**C** **0.750**	**C** **1.000**	**C** **1.000**	**C** **0.875**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**0.946**	**C**
Systemic glucocorticoids, chronic use	**D**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **0.900**	**D** **1.000**	**D** **1.000**	**0.986**	**D**
Antitussives: opioid A., e.g. codein; non-opioid A., e.g. butamirate	**D**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **0.875**	**D** **1.000**	**0.982**	**D**
OSTEOPOROSIS	**Suggested FORTA class**	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland[9] (N=20)** FORTA class / Consensus	**Mean consensus coefficient**	**EURO-FORTA Class** (original FORTA class in parentheses if different from consensus results)

	(2018); if different marked with *							coefficient		
Substance/Group										
Calcium and vitamin D supplements (as prophylaxis for persons ≥65 years)	**A**	**B 0.750**	**A 1.000**	**A 1.000**	**A 0.875**	**A 1.000**	**A 1.000**	**A 0.921**	**0.935**	**A**
Parenteral bisphosphonates (e.g. ibandronate, IV every 3 months)	**A**	**A 1.000**	**B 0.667**	**A 0.750**	**B 1.000**	**B 1.000**	**A 0.875**	**A 1.000**	**0.899**	**A**
Denosumab	**A**	**B 0.875**	**B 0.800**	**B 1.000**	**B 1.000**	**B 1.000**	**A 1.000**	**A 0.972**	**0.950**	**(A) B**
Raloxifene for women	**B**	**B 0.875**	**C 0.800**	**B 0.750**	**B 0.875**	**B 1.000**	**B 1.000**	**A 1.000**	**0.900**	**B**
Bisphosphonates, oral	**B**	**B 0.750**	**B 0.900**	**A 0.750**	**B 0.875**	**B 1.000**	**B 1.000**	**B 0.947**	**0.889**	**B**
Teriparatide	**C**	**C 0.750**	**B 1.000**	**C 0.833**	**C 0.875**	**C 1.000**	**C 1.000**	**C 0.941**	**0.914**	**C**
Alfacalcidol	**C**	**C 1.000**	**C 0.900**	**C 1.000**	**C 1.000**	**C 0.833**	**C 1.000**	**C 1.000**	**0.962**	**C**
Parathormone	**C**	**C 0.875**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 0.875**	**C 1.000**	**0.964**	**C**
Strontium ranelate	**D**	**D 0.875**	**D 1.000**	**D 0.750**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**0.946**	**D**
Nandrolone decanoate	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**1.000**	**D**
Fluoride	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**1.000**	**D**

Hormone replacement therapy (HRT): estrogen, except for perimenopausal)	D	D 0.875	D 1.000	D 0.833	D 1.000	D 1.000	D 0.875	D 0.911	0.928	D
TYPE II DIABETES MELLITUS	**Suggested FORTA class (2018); if different marked with ***	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland[9] (N=20)** FORTA class / Consensus coefficient	**Mean consensus coefficient**	**EURO-FORTA Class** (original FORTA class in parentheses if different from consensus results)
Substance/group										
DPP4 (Dipeptidylpeptidase) Inhibitors	**B**	**B** **1.000**	**A** **1.000**	**B** **1.000**	**A** **1.000**	**B** **1.000**	**B** **1.000**	**A** **0.921**	**0.989**	**B**
Insulin and insulin analogs (if absolutely necessary)	**B**	**B** **0.875**	**B** **0.800**	**A** **0.875**	**A** **0.625**	**B** **0.857**	**B** **1.000**	**B** **0.868**	**0.843**	**B**
Metformin	**B**	**A** **0.750**	**A** **1.000**	**B** **0.750**	**A** **0.875**	**A** **0.929**	**B** **1.000**	**B** **0.868**	**0.882**	**(B)** **A**
GLP1 (Glucagon-Like Peptide-1) analogs	**B**	**C** **0.875**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**B** **0.875**	**B** **0.947**	**0.957**	**B**
Acarbose	**B**	**C** **0.875**	**B** **0.900**	**B** **1.000**	**C** **0.750**	**B** **0.857**	**C** **1.000**	**C** **0.894**	**0.897**	**(B)** **C**
3rd generation sulfonylureas (for example,	**C**	**B** **1.000**	**C** **0.900**	**C** **0.833**	**C** **0.875**	**B** **0.929**	**C** **1.000**	**C** **0.947**	**0.926**	**C**

glimepiride)										
Glinides (for example, nateglinide)	**C**	**C** **1.000**	**C** **0.900**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **0.974**	**0.982**	**C**
PPAR-ɣ Ligands (Peroxisomal Proliferator-Activated Receptor gamma) **Pioglitazone**	**C**	**C** **0.875**	**C** **0.900**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **0.944**	**0.960**	**C**
Rosiglitazone	**D**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**1.000**	**D**
Gliflozins (SGLT-2 inhibitors)	**D**	**B** **0.333**	**B** **0.500**	**D** **1.000**	**C** **0.625**	**B** **0.600**	**C** **1.000**	**C** **0.806**	**0.695**	**(D)** **C**
1st generation sulfonylureas (for example, glibenclamide)	**D**	**C** **0.875**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**0.982**	**D**
DEMENTIA	**Suggested FORTA class (2018); if different marked with ***	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland[9] (N=20)** FORTA class / Consensus coefficient	**Mean consensus coefficient**	**EURO-FORTA Class** (original FORTA class in parentheses if different from consensus results)
Substance/group										

Acetylcholinesterase inhibitors e.g. donepezil, galantamine, rivastigmine (Only if indicated for the present stage of the disease)	**B**	**C 0.750**	**B 0.900**	**B 0.833**	**B 0.875**	**B 0.857**	**B 1.000**	**B 0.895**	**0.873**	**B**
Memantine	**C**	**C 0.875**	**C 0.800**	**B 0.625**	**C 0.875**	**B 0.929**	**C 1.000**	**B 0.947**	**0.864**	**C**
Ginkgo biloba	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**C 0.875**	**0.982**	**D**
Statins	**D**	**D 1.000**	**D 1.000**	**D 0.833**	**D 1.000**	**D 0.929**	**C 1.000**	**D 1.000**	**0.966**	**D**
Selegiline	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**-**	**1.000**	**D**
Nimodipine	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**-**	**1.000**	**D**
Ergoline derivatives	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**-**	**1.000**	**D**
Piracetam	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**1.000**	**D**
Pyritinol	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**-**	**1.000**	**D**
Antioxidants: Vitamin E, selenium, vitamin C	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**1.000**	**D**
Phytotherapeutic agents, e.g. ginseng	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**-**	**1.000**	**D**
Hormone preparations, e.g. DHEA (Dehydroepiandrosterone), testosterone	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 0.975**	**0.996**	**D**
Antiphlogistics, e.g. indomethacin	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**-**	**1.000**	**D**
Desferrioxamine	**D**	**D**	**D**	**D**	**D**	**D**	**D**	**-**	**1.000**	**D**

		1.000	**1.000**	**1.000**	**1.000**	**1.000**	**1.000**			
BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)	**Suggested FORTA class (2018); if different marked with ***	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland[9] (N=20)** FORTA class / Consensus coefficient	**Mean consensus coefficient**	**EURO-FORTA Class** (original FORTA class in parentheses if different from consensus results)
DEPRESSION										
Substance/group										
SSRI (Selective Serotonin Reuptake Inhibitors) Citalopram/escitalopram, sertraline, fluoxetine in the usual dosages	**C**	**C 0.750**	**C 1.000**	**C 0.750**	**C 1.000**	**B 0.917**	**C 1.000**	**C 0.900**	**0.902**	**C**
Mirtazapine (15-45mg/d)	**C**	**C 0.750**	**C 1.000**	**C 0.750**	**C 1.000**	**C 1.000**	**C 1.000**	**C 0.925**	**0.918**	**C**
SNRI (Serotonin-Noradrenalin-Reuptake-Inhibitors) Venlafaxine, duloxetine	**C**	**D 0.750**	**C 1.000**	**C 0.750**	**C 1.000**	**C 0.929**	**C 1.000**	**D 0.875**	**0.901**	**C**

BPSD: PARANOIA, HALLUCINATION	**Suggested FORTA class (2018); if different marked with ***	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland[9] (N=20)** FORTA class / Consensus coefficient	**Mean consensus coefficient**	**EURO-FORTA Class** (original FORTA class in parentheses if different from consensus results)
Substance/group										
Risperidone (initially 0,5-1 mg/d)	**C**	**B** **0.750**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **0.850**	**0.943**	**C**
Melperone (25-150mg/d)	**C**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **0.917**	**0.988**	**C**
Quetiapine (25-200 mg/d)	**C**	**C** **0.875**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**B** **1.000**	**C** **1.000**	**C** **0.921**	**0.971**	**C**
Aripiprazole (2-15 mg/d)	**D**	**C** **0.875**	**C** **1.000**	**C** **1.000**	**D** **1.000**	**D** **1.000**	**C** **1.000**	**D** **0.895**	**0.967**	**(D)** **C**
Haloperidol (initially 0.5 mg/d, max. 3 mg/d)	**C**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**D** **0.750**	**C** **0.786**	**C** **1.000**	**D** **0.921**	**0.922**	**C**
Clozapine (10-50 mg/d)	**D**	**C** **0.625**	**D** **0.900**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **0.950**	**0.925**	**D**

BPSD: RESTLESSNESS, AGITATION, (AGGRESSIVENESS)	**Suggested FORTA class (2018); if different marked with ***	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland[9] (N=20)** FORTA class / Consensus coefficient	**Mean consensus coefficient**	**EURO-FORTA Class** (original FORTA class in parentheses if different from consensus results)
Substance/group										
Trazodone (50-200 mg/d)	**C**	**C 0.875**	**C 1.000**	**C 1.000**	**C 1.000**	**C 0.929**	**C 0.875**	**C 0.895**	**0.939**	**C**
Risperidone (initiallly 0,5-1 mg/d, Maximum 3 mg/d)	**C**	**C 0.875**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 0.900**	**0.968**	**C**
Quetiapine (25-200 mg/d)	**C**	**C 0.875**	**C 0.900**	**C 1.000**	**C 1.000**	**B 1.000**	**C 1.000**	**C 0.921**	**0.957**	**C**
Melperone (25-150 mg/d)	**C**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 0.972**	**0.996**	**C**
Citalopram (10-30mg)	**C**	**D 0.875**	**C 0.900**	**C 1.000**	**C 1.000**	**C 1.000**	**C 0.875**	**C 0.861**	**0.930**	**C**
Clomethiazole (5-15 mg/d)	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 0.944**	**0.992**	**D**
Pipamperone (20-120 mg/d)	**D**	**C 0.875**	**D 1.000**	-	**D 1.000**	**D 0.917**	**D 1.000**	**C 0.947**	**0.957**	**D**

BPSD: SLEEP DISORDERS	**Suggested FORTA class (2018); if different marked with ***	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland[9] (N=20)** FORTA class / Consensus coefficient	**Mean consensus coefficient**	**EURO-FORTA Class** (original FORTA class in parentheses if different from consensus results)
Substance/group										
Slow-release melatonin (2-4 mg)	**C**	**D 1.000**	**C 1.000**	**C 0.833**	**C 1.000**	**C 0.857**	**C 1.000**	**C 0.944**	**0.948**	**C**
Tetracyclic antidepressant Mirtazapine (15-30mg)	**C**	**D 0.750**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 0.850**	**0.943**	**C**
Tricyclic antidepressant Doxepine (25-50 mg)	**C**	**D 1.000**	**C 1.000**	**C 1.000**	**D 0.750**	**D 0.929**	**C 0.875**	**D 1.000**	**0.936**	**D**
Zopiclone (3,75-7,5 mg)	**C**	**C 0.875**	**C 1.000**	**C 1.000**	**C 1.000**	**C 0.857**	**C 0.875**	**D 0.944**	**0.936**	**C**
Zolpidem	**C**	-	**D 1.000**	**C 1.000**	-	**C 0.786**	-	-	**0.929**	**C**
DEPRESSION Prophylaxis and therapy for patients with moderate to major depression		**Netherlands (N=4)** FORTA class / Consensus	**Italy (N=5)** FORTA class / Consensus	**Nordic countries (N=4)** FORTA class / Consensus	**Spain (N=4)** FORTA class / Consensus	**Poland (N=7)** FORTA class / Consensus	**UK/Ireland (N=4)** FORTA class /	**Germany /Austria/Switzerland[9] (N=20)** FORTA	**Mean consensus coefficient**	**EURO-FORTA Class** (original FORTA class in parentheses if different from

	Suggested FORTA class (2018); if different marked with *	coefficient	coefficient	coefficient	coefficient	coefficient	Consensus coefficient	class / Consensus coefficient		consensus results)
Substance/group										
SSRIs (Selective Serotonin Reuptake Inhibitor)	**B**	**C 0.750**	**B 0.900**	**B 1.000**	**B 1.000**	**B 0.857**	**B 1.000**	**B 0.975**	**0.926**	**B**
Sertraline	**B**	**C 0.625**	**B 0.900**	**B 1.000**	**B 1.000**	**B 0.929**	**B 1.000**	**B 0.975**	**0.918**	**B**
Escitalopram	**B**	**B 0.750**	**B 0.900**	**B 1.000**	**B 1.000**	**B 0.929**	**B 1.000**	**B 0.950**	**0.933**	**B**
Citalopram										
Tricyclic antidepressant Nortriptyline	**C**	**B 0.750**	**D 0.900**	**D 1.000**	**D 1.000**	**D 1.000**	**C 1.000**	**C 0.850**	**0.929**	**C**
Tetracyclic antidepressant Mirtazapine	**C**	**C 0.875**	**C 0.900**	**C 0.750**	**C 1.000**	**C 1.000**	**B 1.000**	**C 0.972**	**0.928**	**C**
SNRIs (Serotonin-Noradrenalin Reuptake Inhibitors)	**C**	**C 0.875**	**C 0.875**	**C 0.750**	**C 1.000**	**C 0.857**	**C 0.875**	**C 0.950**	**0.883**	**C**
Venlafaxine										
Duloxetine	**C**	**C 0.875**	**C 0.875**	**C 0.833**	**C 1.000**	**C 0.857**	**C 0.875**	**C 0.950**	**0.895**	**C**
Monoamine oxidase A (MAO) inhibitor Moclobemide	**D***	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 0.975**	**0.996**	**D**
Dopamine and norepinephrine reuptake inhibitor Bupropion	**C**	**C 0.875**	**C 1.000**	**C 1.000**	**C 1.000**	**C 0.929**	**C 1.000**	**C 0.950**	**0.965**	**C**

Vortioxetine	**C**	**C 0.750**	**C 0.800**	**C 1.000**	**C 0.875**	**C 0.917**	**C 0.750**	**-**	**0.849**	**C**
Trazodone	**C**	**C 0.875**	**C 0.900**	**-**	**C 1.000**	**C 0.857**	**C 0.750**	**D 0.900**	**0.880**	**C**
Olanzapine	**C**	**D 0.750**	**C 1.000**	**C 1.000**	**C 0.875**	**C 1.000**	**D 0.875**	**-**	**0.917**	**C**
Quetiapine	**C**	**C 0.875**	**C 1.000**	**D 1.000**	**D 0.750**	**C 1.000**	**D 0.875**	**C 0.900**	**0.914**	**C**
Benzodiazepines: General	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**1.000**	**D**
Long-acting,	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**1.000**	**D**
Short-acting	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**C 0.950**	**0.993**	**D**
St. John's Wort	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 0.972**	**0.996**	**D**
Agomelatine	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 0.950**	**0.993**	**D**
Selective noradrenaline re-uptake inhibitor Reboxetine	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 0.875**	**D 0.857**	**D 1.000**	**D 1.000**	**0.962**	**D**
BIPOLAR DISORDER	**Suggested FORTA class (2018); if different**	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland[9] (N=20)** FORTA class / Consensus coefficient	**Mean consensus coefficient**	**EURO-FORTA Class** (original FORTA class in parentheses if different from consensus results)

	marked with *									
Substance/group										
Quetiapine	**B**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**B 0.929**	**B 1.000**	**B 1.000**	**0.990**	**B**
Lithium	**C**	**B 0.750**	**C 0.800**	**C 1.000**	**B 1.000**	**C 1.000**	**B 1.000**	**B 0.925**	**0.925**	**(C) B**
Valproic acid	**C**	**B 0.875**	**C 0.900**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 0.925**	**0.957**	**C**
Lamotrigine	**C**	**C 1.000**	**C 1.000**	**C 1.000**	**C 0.875**	**C 1.000**	**C 1.000**	**C 0.975**	**0.979**	**C**
Carbamazepine	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**C 1.000**	**D 1.000**	**D 1.000**	**1.000**	**D**

INSOMNIA / SLEEP DISORDERS	**Suggested FORTA class (2018); if different marked with ***	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland[9] (N=20)** FORTA class / Consensus coefficient	**Mean consensus coefficient**	**EURO-FORTA Class** (original FORTA class in parentheses if different from consensus results)
Substance/group										
Melatonin (slow-release)	**B**	**C 0.875**	**B 1.000**	**C 0.833**	**B 0.875**	**B 1.000**	**B 0.875**	**B 0.894**	**0.907**	**B**

ω1-Benzodiazepine agonists Zolpidem	**C**	**D 0.875**	**C 1.000**	**C 0.833**	**C 1.000**	**C 0.786**	**C 1.000**	**C 1.000**	**0.928**	**C**
Zaleplone	**C**	**C 0.833**	**C 1.000**	**C 0.750**	**C 1.000**	**C 0.857**	**C 1.000**	**C 1.000**	**0.920**	**C**
Non-benzodiazepine hypnotic Zopiclone	**C**	**D 0.875**	**C 1.000**	**C 0.833**	**C 1.000**	**C 0.857**	**C 1.000**	**C 0.975**	**0.934**	**C**
Butyrophenone derivative Pipamperone	**C**	**D 0.833**	**C 1.000**	**-**	**C 1.000**	**C 1.000**	**C 0.875**	**C 0.975**	**0.947**	**C**
Melperone	**C**	**D 0.750**	**C 1.000**	**-**	**C 1.000**	**C 1.000**	**C 0.875**	**C 0.974**	**0.933**	**C**
Tetracyclic antidepressant Mirtazapine	**C**	**D 1.000**	**C 1.000**	**C 0.833**	**C 1.000**	**C 1.000**	**C 0.875**	**C 0.925**	**0.948**	**C**
Tricyclic antidepressant Doxepine	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 0.929**	**D 1.000**	**D 1.000**	**0.990**	**D**
Benzodiazepines, e.g. Oxazepam	**D**	**D 1.000**	**D 0.900**	**C 1.000**	**D 0.875**	**D 1.000**	**D 1.000**	**D 0.950**	**0.961**	**D**
(medium half- life) Triazolam (very short half-life)	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 0.875**	**D 0.947**	**0.975**	**D**
Antihistamine Diphenhydramin	**D**	**D 1.000**	**D 1.000**	D **1.000**	**D 1.000**	**D 0.917**	**D 1.000**	**D 1.000**	**0.988**	**D**
Sigma receptor agonist Opipramole	**D**	**D 1.000**	**D 1.000**	-	**D 1.000**	**D 1.000**	**D 1.000**	**D 0.975**	**0.996**	**D**

CHRONIC PAIN	**Suggested FORTA class (2018); if different marked with ***	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland[9] (N=20)** FORTA class / Consensus coefficient	**Mean consensus coefficient**	**EURO-FORTA Class** (original FORTA class in parentheses if different from consensus results)
Substance/group										
Paracetamol (acetaminophen)	**A**	**A 0.875**	**A 1.000**	**A 0.875**	**A 1.000**	**A 0.929**	**A 1.000**	**A 0.868**	**0.935**	**A**
Opioids, e.g. Buprenorphine, oxycodone, hydromorphone	**B**	**B 1.000**	**B 1.000**	**B 1.000**	**B 0.875**	**B 0.786**	**C 0.750**	**B 0.975**	**0.912**	**B**
Primary use of a combination of an agonist and an antagonist, e.g. Tilidine/naloxone	**C**	**C 0.833**	**C 0.875**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 0.974**	**0.955**	**C**
Primary use of a combination of an agonist and an antagonist, e.g. Oxycodone/naloxone	**C**	**C 0.875**	**B 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 0.875**	**C 0.974**	**0.961**	**C**
Morphine	**C**	**C 0.875**	**C 1.000**	**C 0.750**	**C 1.000**	**C 0.917**	**C 0.875**	**C 0.974**	**0.913**	**C**

SSRI (Selective Serotonin Reuptake Inhibitors) / SNRI (Serotonin-Norepinephrine-Reuptake Inhibitor), e.g. venlafaxine (only if absolutely necessary)	**C**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 0.974**	**0.996**	**C**
Antiepileptic agents (only for neuropathic pain) **Pregabalin/gabapentin**	**C**	**C 1.000**	**C 1.000**	**C 1.000**	**C 0.875**	**C 1.000**	**C 1.000**	**C 0.947**	**0.975**	**C**
Carbamazepine	**D**	**C 1.000**	**C 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 0.974**	**0.996**	**D**
Metamizole	**C**	**C 1.000**	**C 0.875**	**-**	**B 1.000**	**B 0.786**	**D 1.000**	**B 0.800**	**0.910**	**C**
Tricyclic antidepressant amitriptyline (does not apply to doses up to 10mg per day)	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 0.875**	**D 1.000**	**0.982**	**D**
NSAIDs (nonsteroidal anti-inflammatory drugs, for long-term use), e.g. **naproxen**	**D**	**D 0.875**	**C 0.800**	**D 0.875**	**D 0.875**	**D 1.000**	**D 1.000**	**D 1.000**	**0.918**	**D**
Cox-2 inhibitors, e.g. celecoxib	**D**	**D 1.000**	**C 0.800**	**D 0.833**	**D 0.875**	**D 1.000**	**D 1.000**	**D 0.921**	**0.918**	**D**

Tramadol	**C**	**-**	**C** **1.000**	**D** **0.875**	**C** **1.000**	**B** **0.929**	**-**	**C** **0.925**	**0.946**	**C**
EPILEPSY	**Suggested FORTA class (2018); if different marked with ***	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland[9] (N=20)** FORTA class / Consensus coefficient	**Mean consensus coefficient**	**EURO-FORTA Class** (original FORTA class in parentheses if different from consensus results)
Substance/group										
Levetiracetam	**B**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**1.000**	**B**
Lamotrigine	**B**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**1.000**	**B**
Gabapentin	**B**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**B** **0.875**	**B** **0.911**	**0.969**	**B**
Pregabalin	**C**	**B** **1.000**	**B** **1.000**	**B** **0.833**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **0.941**	**0.968**	**C**
Lorazepam (emergency use)	**B**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**B** **0.929**	**B** **1.000**	**B** **0.971**	**0.986**	**B**
Lorazepam (long-term use)	**D**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **0.941**	**0.992**	**D**
Topiramate	**B**	**B** **1.000**	**B** **1.000**	**C** **1.000**	**B** **1.000**	**B** **0.857**	**B** **1.000**	**B** **0.853**	**0.959**	**B**
Valproic acid	**C**	**B** **1.000**	**C** **1.000**	**C** **0.750**	**C** **0.875**	**C** **1.000**	**C** **0.875**	**C** **0.971**	**0.924**	**C**
Eslicarbazepine	**C**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**1.000**	**C**

Lacosamide	**C**	**C 1.000**	**C 1.000**	**C 1.000**	**C 0.875**	**C 1.000**	**C 1.000**	**B 0.969**	**0.978**	**C**
Zonisamide	**C**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**1.000**	**C**
Carbamazepine	**C**	**C 1.000**	**C 1.000**	**C 0.750**	**C 0.875**	**C 1.000**	**C 1.000**	**C 0.971**	**0.942**	**C**
Diazepam (emergency use)	**C**	**C 0.750**	**C 1.000**	**B 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 0.971**	**0.960**	**C**
Diazepam (long-term use)	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**1.000**	**D**
Midazolam (emrgency use)	**C**	**B 0.875**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 0.875**	**C 0.844**	**0.942**	**C**
Midazolam (long-term use)	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 0.941**	**0.992**	**D**
Oxcarbazepine	**C**	**C 1.000**	**C 1.000**	**D 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**1.000**	**C**
Phenytoin	**D**	**D 1.000**	**D 1.000**	**D 0.875**	**D 1.000**	**D 1.000**	**D 0.875**	**D 1.000**	**0.964**	**D**
Phenobarbital	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**1.000**	**D**
Ethosuximide	**D**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**1.000**	**D**

PARKINSON'S DISEASE	**Suggested FORTA class**	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland[9] (N=20)** FORTA class / Consensus	**Mean consensus coefficient**	**EURO-FORTA Class** (original FORTA class in parentheses if different from consensus results)

	(2018); if different marked with *							coefficient		
Substance/group										
L-DOPA	**A**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**A** **1.000**	**B** **0.875**	**A** **1.000**	**0.982**	**A**
COMT (Catechol-O-Methyltransferase) Inhibitor Entacapone, opicapon	**B**	**B** **0.875**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**B** **0.947**	**0.975**	**B**
Dopamine agonists, e.g. **Ropinirole**	**B**	**B** **1.000**	**C** **1.000**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**C** **1.000**	**B** **1.000**	**1.000**	**B**
Pramipexole	**B**	**B** **1.000**	**C** **1.000**	**B** **1.000**	**B** **1.000**	**C** **0.929**	**C** **1.000**	**C** **0.973**	**0.986**	**(B)** **C**
Piribedil, quinagolide, rotigotine	**B**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**B** **1.000**	**B** **0.929**	**B** **0.875**	**C** **0.973**	**0.968**	**B**
MAO-B inhibitors **Rasagiline**	**C**	**C** **0.875**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **0.921**	**0.971**	**C**
Selegiline	**C**	**C** **0.875**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**D** **1.000**	**C** **1.000**	**D** **1.000**	**0.982**	**C**
Glutamate antagonists Amantadine	**D**	**C** **0.875**	**D** **1.000**	**C** **1.000**	**D** **1.000**	**D** **0.929**	**D** **0.875**	**D** **1.000**	**0.954**	**D**
Bromocriptine, cabergoline	**D**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**D** **1.000**	**1.000**	**D**

Anticholinergics Biperidene	**D**	**D 1.000**	**D 1.000**	**D 0.875**	**D 1.000**	**D 1.000**	**D 0.875**	**D 1.000**	**0.964**	**D**
INCONTINENCE Drug therapy for urge incontinence	**Suggested FORTA class (2018); if different marked with ***	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland[9] (N=20)** FORTA class / Consensus coefficient	**Mean consensus coefficient**	**EURO-FORTA Class** (original FORTA class in parentheses if different from consensus results)
Substance/group										
Fesoterodine	**B**	**C 0.750**	**B 0.875**	**B 0.667**	**B 0.875**	**B 1.000**	**C 1.000**	**B 0.889**	**0.865**	**B**
Tolterodine	**C**	**C 1.000**	**C 1.000**	**C 0.833**	**C 0.875**	**C 1.000**	**C 1.000**	**C 0.971**	**0.954**	**C**
Trospium chloride	**C**	**C 1.000**	**C 1.000**	**C 0.750**	**C 1.000**	**C 1.000**	**C 1.000**	**C 0.941**	**0.956**	**C**
Extended-release Oxybutynin	**C**	**D 1.000**	**C 1.000**	**C 0.833**	**C 1.000**	**C 1.000**	**C 1.000**	**C 0.971**	**0.972**	**C**
Immediate-release Oxybutynin	**D**	**D 1.000**	**D 1.000**	**D 0.833**	**D 1.000**	**D 1.000**	**D 1.000**	**D 1.000**	**0.976**	**D**

GASTROINTESTINAL ILLNESSES/ CONCOMITANT THERAPY WITH NSAIDs	**Suggested FORTA class (2018); if different marked with ***	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland[9] (N=20)** FORTA class / Consensus coefficient	**Mean consensus coefficient**	**EURO-FORTA Class** (original FORTA class in parentheses if different from consensus results)
Substance/group										
Proton pump inhibitors (PPI), only if absolutely necessary	**B**	**B 0.875**	**B 0.800**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**B 0.921**	**0.942**	**B**
H_2 receptor antagonists	**C**	**C 1.000**	**C 0.800**	**C 1.000**	**C 1.000**	**C 0.929**	**C 1.000**	**C 1.000**	**0.961**	**C**

Anemia	**Suggested FORTA class** (2018); if different marked with *	Netherlands **(N=4)** **FORTA class / Consensus coefficient**	**Italy (N=5)** **FORTA class / Consensus coefficient**	**Nordic countries (N=4)** **FORTA class / Consensus coefficient**	**Spain (N=4)** **FORTA class / Consensus coefficient**	**Poland (N=7)** **FORTA class / Consensus coefficient**	**UK/Ireland (N=4)** **FORTA class / Consensus coefficient**	**Germany /Austria/Switzerland[9] (N=20)** **FORTA class / Consensus coefficient**	**Mean consensus coefficient**	**EURO-FORTA Class** **(original FORTA class in parentheses if different from consensus results)**
Substance/group										

Substitution (iron, vitamin B12, folic acid in cases of deficiency)	**A**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 0.929**	**A 1.000**	**A 1.000**	**0.990**	**A**
Erythropoetin-stimulating agents (ESA) in patients with renal insufficiency	**A**	**A 1.000**	**A 1.000**	**A 0.875**	**A 1.000**	**A 1.000**	**A 0.875**	**A 0.972**	**0.960**	**A**
Iron substitution in patients with cardiac insufficiency **With proof of iron deficiency**	**See cardiac insufficiency**	-	-	-	-	-	-	-	-	-

Vaccinations	**Suggested FORTA class** (2018); if different marked with *	Netherlands **(N=4)** **FORTA class / Consensus coefficient**	**Italy (N=5)** **FORTA class / Consensus coefficient**	**Nordic countries (N=4)** **FORTA class / Consensus coefficient**	**Spain (N=4)** **FORTA class / Consensus coefficient**	**Poland (N=7)** **FORTA class / Consensus coefficient**	**UK/Ireland (N=4)** **FORTA class / Consensus coefficient**	**Germany /Austria/Switzerland[9] (N=20)** **FORTA class / Consensus coefficient**	**Mean consensus coefficient**	**EURO-FORTA Class** **(original FORTA class in parentheses if different from consensus results)**
Substance/group										
Annual influenza immunizations	**A**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 0.857**	**A 1.000**	**A 1.000**	**0.980**	**A**
Pneumococcal immunizations for persons ≥ 65 years	**A**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 0.929**	**A 1.000**	**A 1.000**	**0.990**	**A**

Shingles (Herpes Zoster) Vaccination	**A**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**B 0.750**	**A 1.000**	**A 1.000**	**0.964**	**A**

ONCOLOGICAL DISEASES: SOLID TUMORS	**Suggested FORTA class (2018); if different marked with ***	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland[9] (N=20)** FORTA class / Consensus coefficient	**Mean consensus coefficient**	**EURO-FORTA Class** (original FORTA class in parentheses if different from consensus results)
INDICATION Substance/group										
BREAST CANCER Adjuvant therapy										
Hormone therapy, e.g. Tamoxifen	**B**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**B 0.954**	**0.993**	**B**
Aromatase inhibitors	**B**	**B 1.000**	**B 1.000**	**B 1.000**	**B 0.875**	**B 1.000**	**B 1.000**	**B 1.000**	**0.982**	**B**
Immunotherapy / "Targeted" therapy Trastuzumab	**B**	**C 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**1.000**	**B**
Chemotherapy, e.g. CMF (Combination Cyclophosphamide,	**C**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**1.000**	**C**

Methotrexate, 5-Fluorouracil)										
AC/EC Regimen (Anthracycline/ Epirubicin, Cyclophosphamide)	**C**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**1.000**	**C**
BREAST CANCER Advanced Stage										
Hormone therapy, e.g. tamoxifen, aromatase inhibitors	**B**	**B 1.000**	**B 1.000**	**-**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**1.000**	**B**
Immunotherapy/ Targeted Therapy Trastuzumab/ lapatinib	**B**	**C 1.000**	**B 1.000**	**-**	**B 1.000**	**B 1.000**	**B 1.000**	**-**	**1.000**	**B**
Chemotherapy, e.g. anthracyclins, taxanes	**C**	**C 1.000**	**C 1.000**	**-**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**1.000**	**C**
VEGF (Vascular Endothelial Growth Factor) Inhibition Bevacizumab	**D**	**D 1.000**	**D 1.000**	**-**	**D 1.000**	**D 1.000**	**D 1.000**	**-**	**1.000**	**D**
COLORECTAL CARCINOMA Adjuvant Therapy										
FOLFOX Regimen (Folinic acid, Fluorouracil, Oxaliplatin)	**C**	**C 1.000**	**C 1.000**	**-**	**C 1.000**	**C 1.000**	**C 1.000**	**C 1.000**	**1.000**	**C**
5-Fluorouracil based infusion regimen	**C**	**C 1.000**	**C 1.000**	**-**	**C 1.000**	**C 1.000**	**C 1.000**	**B 1.000**	**1.000**	**C**

Capecitabine	**C**	**C** **1.000**	**C** **1.000**	**-**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**B** **1.000**	**1.000**	**C**
COLORECTAL CARCINOMA Advanced stage										
Chemotherapy FOLFOX (Folinic acid, Fluorouracil, Oxaliplatin)	**C**	**C** **1.000**	**C** **1.000**	**-**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**1.000**	**C**
VEGF (Vascular Endothelial Growth Factor) Inhibition Bevacizumab	**C**	**C** **1.000**	**C** **1.000**	**-**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**-**	**1.000**	**C**
EGFR (Epidermal-Growth-Factor-Receptor) Inhibition										
Cetuximab	**C**	**C** **1.000**	**C** **1.000**	**-**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**1.000**	**C**
Panitumumab	**C**	**C** **1.000**	**C** **1.000**	**-**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**-**	**1.000**	**C**
BRONCHIAL CARCINOMA Adjuvant therapy										
Adjuvant chemotherapy (Cisplatin-based)	**C**	**C** **1.000**	**C** **1.000**	**-**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**1.000**	**C**
BRONCHIAL CARCINOMA Advanced Stage										
Docetaxel	**B**	**C** **1.000**	**B** **1.000**	**-**	**B** **1.000**	**B** **1.000**	**B** **0.875**	**C** **1.000**	**0.979**	**B**
Vinorelbin	**B**	**C** **1.000**	**B** **1.000**	**-**	**B** **1.000**	**B** **1.000**	**B** **0.875**	**-**	**0.975**	**B**
Primary combination therapy Cisplatin/gemcitabi	**C**	**C** **1.000**	**C** **1.000**	**-**	**C** **1.000**	**C** **1.000**	**C** **1.000**	**-**	**1.000**	**C**

n, or cisplatin/vinorelbin										
GASTRIC CANCER										
ECF Regime (Epirubicin, Cisplatin, 5-Fluorouracil)	**B**	**C 1.000**	**B 1.000**	**-**	**B 1.000**	**B 1.000**	**C 1.000**	**-**	**1.000**	**B**
ONCOLOGICAL DISEASES HEMATOLOGICAL NEOPLASIAS	**Suggested FORTA class (2018); if different marked with ***	**Netherlands (N=4)** FORTA class / Consensus coefficient	**Italy (N=5)** FORTA class / Consensus coefficient	**Nordic countries (N=4)** FORTA class / Consensus coefficient	**Spain (N=4)** FORTA class / Consensus coefficient	**Poland (N=7)** FORTA class / Consensus coefficient	**UK/Ireland (N=4)** FORTA class / Consensus coefficient	**Germany /Austria/Switzerland[9] (N=20)** FORTA class / Consensus coefficient	**Mean consensus coefficient**	**EURO-FORTA Class** (original FORTA class in parentheses if different from consensus results)
INDICATION Substance/group										
MDS (Myelodysplastic syndrome) Azacytidine	**B**	**B 1.000**	**B 1.000**	**-**	**B 1.000**	**B 1.000**	**B 0.875**	**-**	**0.975**	**B**
AML (Acute myeloid leukemia) Anthracyclines + cytosine arabinoside (cytarabine)	**B**	**B 1.000**	**B 1.000**	**-**	**B 1.000**	**B 1.000**	**C 1.000**	**-**	**1.000**	**B**
CLL (Chronic lymphatic leukemia)	**B**	**B 1.000**	**B 1.000**	**-**	**B 1.000**	**B 1.000**	**B 0.875**	**-**	**0.979**	**B**

Chlorambucil, Fludarabin, Bendamustin										
CLL Obinutuzumab	**B**	**B 1.000**	**B 1.000**	**-**	**B 1.000**	**B 1.000**	**B 0.875**	**-**	**0.975**	**B**
CLL Rituximab	**B**	**B 1.000**	**B 1.000**	**-**	**B 1.000**	**B 1.000**	**B 0.875**	**-**	**0.975**	**B**
Multiple myeloma **Primary therapy with** **Prednisolone**	**B**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**B 0.875**	**-**	**0.979**	**B**
Thalidomide	**B**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**B 0.875**	**-**	**0.979**	**B**
Melphalan	**B**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**B 0.875**	**-**	**0.979**	**B**
Bortezomib	**B**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**B 0.875**	**-**	**0.979**	**B**
Lenalidomide	**B**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**B 0.875**	**-**	**0.979**	**B**
CLL Ibrutinib	**C**	**C 1.000**	**C 1.000**	**-**	**C 1.000**	**C 1.000**	**C 1.000**	**-**	**1.000**	**C**
CLL Idelalisib	**C**	**C 1.000**	**C 1.000**	**-**	**C 1.000**	**C 1.000**	**C 1.000**	**-**	**1.000**	**C**
ONCOLOGICAL		**Netherlands (N=4)** FORTA class	**Italy (N=5)** FORTA class	**Nordic countries (N=4)** FORTA class	**Spain (N=4)** FORTA class	**Poland (N=7)** FORTA class	**UK/Ireland (N=4)**	**Germany /Austria/Switzerland[9] (N=20)**	**Mean consensus**	**EURO-FORTA Class** (original

SUPPORTIVE THERAPY	**Suggested FORTA class (2018); if different marked with ***	/ Consensus coefficient	/ Consensus coefficient	/ Consensus coefficient	/ Consensus coefficient	/ Consensus coefficient	FORTA class / Consensus coefficient	FORTA class / Consensus coefficient	**coefficient**	FORTA class in parentheses if different from consensus results)
Substance/group										
G-CSF (Granulocyte Colony Stimulation Factor)	**A**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 0.875**	**A 1.000**	**0.982**	**A**
Antiemetic agents (e.g. 5-HT receptor inhibitors)	**A**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**A 1.000**	**1.000**	**A**
Erythropoesis Stimulating Agents, ESA	**B**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**B 1.000**	**B 0.962**	**0.995**	**B**

*This substance or indication was suggested by the participating experts during the course of Round 1 and evaluated by the experts during Round 2, see second table below.

R1= Round 1

R2= Round 2

Delphi Expert Consensus Validation[5]

F	O	R	T	A
A	B	C	D	

NEW SUBSTANCES/INDICATIONS SUGGESTED BY EXPERTS
Results to be corroborated in future consensus/research projects

Classification of long-term medications†
for the pharmacotherapy of older patients
by indication/diagnosis, ranked according to FORTA classification

(†long-term defined as > 4 weeks. Please note that the distinction between acute/chronic may not always be clear-cut; exceptions are noted)

EXISTING INDICATION vaccinations	**Rater-based FORTA Class (bold if: κ > 0.500, rater number ≥ 10 and label distance < 2)[9]**	**Nr. of countries[9]**	**Mean κ-Index[9]**	**Expert ratings on a numerical scale: A=1, B=2, C=3, D=4 Mean[9]; Mode[9]**	**Selection of pertinent comments given by participating experts during the consensus procedure**
Substance/group					
COVID-19 vaccination	**A**	5	0.982	1; 1	

REFERENCES

1. Wehling M. Drug therapy in the elderly: too much or too little, what to do? A new assessment system: fit for the aged FORTA. Dtsch Med Wochenschr 2008; 133: 2289-91.
2. Wehling M. Multimorbidity and polypharmacy: how to reduce the harmful drug load and yet add needed drugs in the elderly? Proposal of a new drug classification: fit for the aged. J Am Geriatr Soc 2009; 57: 560-561.
3. Wehling M, Burkhardt H. Arzneitherapie für Ältere. Springer-Verlag, Heidelberg, 3. Auflage 2013.
4. Wehling M, Ed., Drug Therapy for the Elderly. Springer-Verlag, Wien 2013
5. Kuhn-Thiel AM. et al. Consensus validation of the FORTA (Fit fOR The Aged) List: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging. 2014; 31(2): 131-140.
6. Wehling M. et al. VALFORTA: a randomized trial to validate the FORTA (Fit fOR The Aged) classification. Age Ageing Jan 18, 2016, doi: 10.1093/ageing/afv200 [Epub ahead of print]
7. Wehling M. How to Use the FORTA ("Fit fOR The Aged") List to Improve Pharmacotherapy in the Elderly. Drug Res 2015, ePub
8. Pazan F. et al. The EURO-FORTA (Fit fOR The Aged) List: International Consensus Validation of a Clinical Tool for Improved Drug Treatment in Older People. Drugs Aging. 2018; 35(1):61-71.
9. Pazan F. et al. The FORTA (Fit fOR The Aged) List 2021: Fourth Version of a Validated Clinical Aid for Improved Pharmacotherapy in Older Adults. Drugs Aging 2022; 39: 245-247.

SUMMARY OF STATISTICAL METHODS
(The following descriptions of the statistical methods and calculations are based on the first version of the FORTA List[5]. Former definitions and explanations are adopted unchanged.)

Consensus Coefficient[5]

Consensus parameters were generated by calculating the percentage of experts' FORTA ratings (minus abstentions) agreeing with the original FORTA values, both overall and for each item separately (n = 266). The coefficients were then corrected (cons_corr) to weight the degree of deviation between the experts' individual FORTA ratings, expressed in terms of range class, from 0-3 as defined:

- Range = 0: unanimity among all experts, full weight**;**
- Range = 1: greatest range only from A to B or B to C, or C to D (neighboring classes), ½ weight**;**
- Range = 2: greatest distance from A to C or B to D, weight=0**;**
- Range = 3: greatest distance from A to D, weight=0.

Confirmation/determination of FORTA labels[5]

In order to compare the rater-based FORTA labels with the original author-based labels, the labels A, B, C and D were transformed as follows[5]:

A→ 1
B → 2
C → 3
D → 4

These numerical "grades" were used for the calculation of arithmetic mean. The rater-based FORTA labels are derived from the arithmetic mean from Round 1, or if re-evaluated, from Round 2. The range for each grade was set at:

If $1 \leq m < 1.5$ → FORTA Class **A**
If $1.5 \leq m < 2.5$ → FORTA Class **B**
If $2.5 \leq m < 3.5$ → FORTA Class **C**

If m ≥ 3.5 → FORTA Class **D**

m= arithmetic mean based on the grades 1-4

The results of The Delphi Consensus Validation Procedure confirmed the original FORTA labels for 96,9% of all substances (n=256, substances with low number of raters, less than four, are not taken into consideration); for 8 substances, the FORTA labels changed over the course of two rounds in all participating countries. All consensus-based FORTA ratings are listed in bold print**: A B C D**, and the original author-based FORTA ratings are supplied in parentheses: (A) (B) (C) (D).

Asterisks in the first table mark substances or indications suggested by the panel members during the course of Round 1 and assessed by the experts during Round 2. Besides, the number of countries whose panel members suggested a substance was ≥4.

Selection process for new substances and indications[5]

- A total of 1 substance was accepted for potential addition to the revised FORTA List. Due to the large number of substances suggested, a selection procedure was adopted: acceptance of all substances suggested by ≥ 4 countries during Round 1, and all suggested indication areas
    - 1 new substance belonging to pre-existing FORTA indications was added to the EURO-FORTA list
- A kappa index was generated for each of those added substances to analyze the distribution of the raters' FORTA labels given. The kappa index is defined as the (proportion of "matching" labels – 0.25) / 0.75. This gives due consideration to the fact that a figure of 25% can theoretically be attained by chance alone with this particular constellation (the choice of 4 distinct labels, as with multiple choice).

Mean and mode were calculated according to the numerical scale used for the original FORTA substances

A → 1
B → 2
C → 3
D → 4

If $1 \leq m < 1.5$ → FORTA Class **A**

If $1.5 \leq m < 2.5$ → FORTA Class **B**

If $2.5 \leq m < 3.5$ → FORTA Class **C**

If $m \geq 3.5$ → FORTA Class **D**

m= arithmetic mean based on the grades 1-4

- The new substance had a kappa index higher than 0.500. Suggesting a high level of inter-rater agreement for this substance